Clarivate sells Life Sciences unit for $600 million

• Clarivate (NYSE:CLVT) agreed to sell its Life Sciences & Healthcare segment to Altaris for $600 million.
• The company will receive $500 million in cash at closing, plus $25 million deferred and a $75 million seller note.
• Clarivate will refocus on Academia & Government and Intellectual Property businesses after the sale.

Clarivate (NYSE:CLVT) said it has agreed to sell its Life Sciences & Healthcare (LS&H) segment to Altaris for a total consideration of $600 million.

The transaction includes $500 million in cash at closing, $25 million in deferred payments, and a $75 million seller note.

The company said proceeds will be used primarily to reduce debt and strengthen its balance sheet.

Clarivate will reclassify the LS&H segment as discontinued operations following the transaction.

The company also expects a non-cash goodwill impairment charge of $225 million to $250 million related to the LS&H segment.

Clarivate said this impairment will not affect its 2026 full-year outlook metrics.

After the divestiture, Clarivate will focus on its Academia & Government and Intellectual Property business segments.